{"filing":{"accession_number":"0001549595-26-000038","cik":"0001549595","ticker":"NRIX","company_name":"Nurix Therapeutics, Inc.","form":"8-K","filing_date":"2026-07-09","report_date":null,"primary_document":"nrix-20260709.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1549595/000154959526000038/nrix-20260709.htm"},"events":[{"id":16833,"run_id":15060,"accession_number":"0001549595-26-000038","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Nurix issued a press release on July 9, 2026, announcing financial results for the fiscal quarter ended May 31, 2026, including revenue of $9.0 million, R\u0026D expenses of $87.7 million, and a net loss of $89.5 million ($0.81 per share). The disclosure is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases. While the press release also highlights the Roche collaboration agreement, the primary disclosure is the quarterly financial results.","company_name":"Nurix Therapeutics, Inc.","ticker":"NRIX","filing_date":"2026-07-09","form":"8-K","submitted_at":null,"items":[{"id":15049,"accession_number":"0001549595-26-000038","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Nurix issued a press release on July 9, 2026, announcing financial results for the fiscal quarter ended May 31, 2026, including revenue of $9.0 million, R\u0026D expenses of $87.7 million, and a net loss of $89.5 million ($0.81 per share). The disclosure is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases. While the press release also highlights the Roche collaboration agreement, the primary disclosure is the quarterly financial results.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T10:38:05.823982+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":15049,"accession_number":"0001549595-26-000038","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Nurix issued a press release on July 9, 2026, announcing financial results for the fiscal quarter ended May 31, 2026, including revenue of $9.0 million, R\u0026D expenses of $87.7 million, and a net loss of $89.5 million ($0.81 per share). The disclosure is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases. While the press release also highlights the Roche collaboration agreement, the primary disclosure is the quarterly financial results.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T10:38:05.823982+00:00","company_name":"Nurix Therapeutics, Inc.","ticker":"NRIX","filing_date":"2026-07-09"}]}